Anti-TIM-3 antibodies
Anti-TIM-3 antibodies are disclosed, as well as pharmaceutical compositions comprising such antibodies, and uses and methods using the same, such as in the treatment of cancer, infectious diseases, or T-cell dysfunctional disorders. Bispecific antibodies against TIM-3 and other targets are also disclosed, with preferred embodiment of a bispecific antibody against TIM-3 and CD3.
1. An antibody, or antigen binding fragment, which is capable of binding to TIM-3, optionally isolated, having at least one light chain variable region incorporating the following CDRs:
LC-CDR1:
(SEQ ID NO: 47)
SGSSSNIGNNYVS
LC-CDR2:
(SEQ ID NO: 48)
GNNWRPS
LC-CDR3:
(SEQ ID NO: 49)
ETWDSSLSAGV;
and having at least one heavy chain variable region incorporating the following CDRs:
HC-CDR1:
(SEQ ID NO: 61)
GYYWS,
or
(SEQ ID NO: 52)
GGSFSGYYWS
HC-CDR2:
(SEQ ID NO: 53)
EINHSGSTNYNPSLKS
HC-CDR3:
(SEQ ID NO: 54)
GYVAGFDY.
2. The antibody, or antigen binding fragment, of claim 1 , wherein the antibody or antigen binding fragment is cytotoxic.
3. The antibody, or antigen binding fragment, of claim 1 , wherein the antibody or antigen binding fragment is effective to restore T-cell function in T-cells exhibiting T-cell exhaustion or T-cell anergy.
4. The antibody or antigen binding fragment, of claim 1 , which is a bispecific antibody or a bispecific antigen binding fragment comprising (i) an antigen binding fragment according to claim 1 , and (ii) an antigen binding domain which is capable of binding to a target protein other than TIM-3.
5. The antibody, or antigen binding fragment, of claim 4 , wherein the antigen binding domain which is capable of binding to a target protein other than TIM-3 is capable of binding to CD3 or a CD3 polypeptide.
6. The antibody or antigen binding fragment of claim 1 , comprising a heavy chain and a light chain variable region sequence, wherein:
the heavy chain sequence has at least 70% sequence identity to the heavy chain sequence of SEQ ID NO:50 or 51, and
the light chain sequence has at least 70% sequence identity to the light chain sequence of SEQ ID NO:45 or 46.
7. The antibody or antigen binding fragment of claim 1 , comprising a heavy chain and a light chain variable region sequence, wherein:
the heavy chain sequence has at least 85% sequence identity to the heavy chain sequence of SEQ ID NO:50, and
the light chain sequence has at least 85% sequence identity to the light chain sequence of SEQ ID NO:45.
8. The antibody or antigen binding fragment of claim 1 , comprising a heavy chain and a light chain variable region sequence, wherein:
the heavy chain sequence has at least 85% sequence identity to the heavy chain sequence of SEQ ID NO:51, and
the light chain sequence has at least 85% sequence identity to the light chain sequence of SEQ ID NO:46.
9. The antigen binding fragment of claim 1 , wherein the antigen binding fragment is a Fab fragment or scFv fragment.
10. The antibody of claim 1 , wherein the antibody comprises a human constant region selected from IgG1, IgG2, IgG3 and IgG4.
11. A method for treating cancer that expresses TIM-3, comprising administering an antibody or antigen binding fragment to a patient suffering from the cancer, wherein the antibody, or antigen binding fragment, is capable of binding to TIM-3, optionally isolated, having at least one light chain variable region incorporating the following CDRs:
LC-CDR1:
(SEQ ID NO: 47)
SGSSSNIGNNYVS
LC-CDR2:
(SEQ ID NO: 48)
GNNWRPS
LC-CDR3:
(SEQ ID NO: 49)
ETWDSSLSAGV;
and having at least one heavy chain variable region incorporating the following CDRs:
HC-CDR1:
(SEQ ID NO: 61)
GYYWS,
or
(SEQ ID NO: 52)
GGSFSGYYWS
HC-CDR2:
(SEQ ID NO: 53)
EINHSGSTNYNPSLKS
HC-CDR3:
(SEQ ID NO: 54)
GYVAGFDY.
12. The method according to claim 11 , wherein the cancer is a cancer of a tissue selected from the group consisting of lung, kidney, bladder, liver, stomach, cervix, nasopharynx, oral cavity, oesophagus, larynx, salivary gland, tongue, tonsil, trachea, skin, blood, colon and breast.
13. The method according to claim 11 , wherein the cancer is selected from the group consisting of lung cancer, non-small cell lung cancer (NSCLC), renal cancer, renal cell carcinoma, bladder cancer, bladder carcinoma, liver cancer, hepatoma, stomach cancer, cervical cancer, nasopharyngeal cancer, oral cavity cancer, oesophageal cancer, laryngeal cancer, salivary gland cancer, tongue cancer, tonsil cancer, tracheal cancer, skin cancer, melanoma, metastatic melanoma, haematologic cancer, lymphoma, Hodgkin's lymphoma, colon cancer, colon carcinoma and breast cancer.